Evidence map›Paper›PMID 38804044›Full record

ArticleActa biochimica et biophysica Sinica2024

EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma.

Shushan Guo, Qiongwei Tang, Xuejie Gao, Liangning Hu, Ke Hu, Hui Zhang, Qikai Zhang, Yue Lai, Yujie Liu, Zhuning Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shushan GuoShanghai Clinical College, Anhui Medical University, Shanghai 200072, China.
Qiongwei TangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Xuejie GaoDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Liangning HuDepartment of Hematology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
Ke HuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Hui ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Qikai ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yue LaiDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yujie LiuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Zhuning WangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Shuaikang ChangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yifei ZhangDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Huifang HuDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Dong AnDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Yu PengDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Haiyan CaiDepartment of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Jumei ShiShanghai Clinical College, Anhui Medical University, Shanghai 200072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic modifications play an important role in cellular senescence, and enhancer of zeste homolog 2 (EZH2) is a key methyltransferase involved in epigenetic remodeling in multiple myeloma (MM) cells. We have previously demonstrated that GSK126, a specific EZH2 inhibitor, exhibits anti-MM therapeutic efficacy and safety

Indexed as

Cellular SenescenceEnhancer of Zeste Homolog 2 ProteinMAP Kinase Signaling SystemMultiple MyelomaCell Line, TumorHumansIndolesPhosphorylationPyridonesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanGSK-2816126IndolesPyridonescellular senescenceEZH2Lamin B1multiple myelomaRRM2

Identifiers

PMID38804044
PMCPMC11322866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.